Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inducing host acceptance to encapsulated xenogeneic myoblasts.

C Rinsch1, G Peduto, B L Schneider

  • 1Division of Surgical Research & Gene Therapy Center, Lausanne, Switzerland.

Transplantation
|March 10, 2001
PubMed
Summary

Transient immunosuppression with FK506 enables long-term acceptance of encapsulated xenogeneic cells. This approach facilitates the replacement of cell implants without additional immunosuppression, paving the way for advanced cell-based therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Q fever outbreak in the terraced vineyards of Lavaux, Switzerland.

New microbes and new infections·2014
Same author

Growth, efficiency, and yield of commercial broilers from 1957, 1978, and 2005.

Poultry science·2014
Same author

Measurement of autophagy flux in the nervous system in vivo.

Cell death & disease·2013
Same author

Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.

Journal of Parkinson's disease·2013
Same author

An in vivo ultrahigh field 14.1 T (1) H-MRS study on 6-OHDA and α-synuclein-based rat models of Parkinson's disease: GABA as an early disease marker.

NMR in biomedicine·2012
Same author

Imaging brain amyloid deposition using grating-based differential phase contrast tomography.

NeuroImage·2012

Area of Science:

  • Biotechnology
  • Immunology
  • Regenerative Medicine

Background:

  • Cell encapsulation is a promising strategy for chronic delivery of therapeutic proteins like erythropoietin.
  • Encapsulated xenogeneic cells show varied survival rates in different tissues, indicating incomplete immune evasion.
  • Short-term immunosuppression can enhance the survival of subcutaneous cell implants.

Purpose of the Study:

  • To investigate the mechanisms underlying the acceptance of encapsulated xenogeneic cells after transient immunosuppression.
  • To determine the duration and requirements for developing unresponsiveness to encapsulated xenografts.
  • To assess the potential for replacing cell implants without re-administering immunosuppressants.

Main Methods:

  • Fischer rats received encapsulated murine C2C12 myoblasts with FK506 immunosuppression (1 or 4 weeks).

Related Experiment Videos

  • Animals were challenged with a second implant after 9 weeks to assess xenograft acceptance.
  • The necessity of the encapsulation membrane for immune protection was evaluated by challenging with unencapsulated cells.

    • Main Results:

    • A 4-week FK506 treatment resulted in acceptance of both primary and secondary encapsulated cell implants.
    • Animals treated for only 1 week rejected both implants, indicating insufficient immunosuppression duration.
    • Unencapsulated cells were rejected, confirming the critical role of the polymer membrane in immune protection.
    • Host unresponsiveness to encapsulated xenografts persisted for at least 7 months without ongoing immunosuppression.

    Conclusions:

    • Transient FK506 immunosuppression can induce long-term acceptance of encapsulated xenogeneic cells in subcutaneous tissue.
    • This method allows for the replacement of cell-laden capsules without further immunosuppression.
    • The findings support the clinical relevance of this approach for long-term, cell-based therapeutic strategies.